Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis

Nguyen, Chu Van; Nguyen, Quang T.; Vu, Ha Thi; Phung, Huyen Thi; Pham, Khoa Hong; Le, Roanh Dinh

doi:10.1177/1533033820983081

Cited by 7 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study found that BCL2 was strongly linked to better clinicopathological factors, including small size of tumors, lower histological grade, less lymph node metastasis, and lymphatic invasion 48 . In Czech, study by Čečka et al, 30 revealed no significant correlation between BCL2 with tumor size and grade.…”

Section: Discussionmentioning

confidence: 99%

Correlation Expression between P52 and BCL2 among Iraqi Women with Breast Carcinoma

Al-Sudani¹,

AlKhafaji²,

Mohammed³

2023

Baghdad Sci.J

View full text Add to dashboard Cite

Breast cancer is the leading cause of death in women and ranks second in cancer-related mortality in worldwide. NF-𝜅B2(P52) is one of the mammalian NF-κB transcription factor family that expressed in breast tumors. BCL2 is an anti-apoptotic protein that also acts as a medical prognostic biomarker for breast carcinoma. This research was aimed to find out the IHC expression of P52 and BCL2 in 67 histological specimens of breast cancer patients and evaluate their correlation with clinicopathological features. Protein IHC expression of BCL2 and P52 was observed in 45 and 46 respectively. There was no correlation between P52 and BCL2 expression with any clinicopathological parameters, while a strong correlation between protein expression of P52 and BCL2.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation Expression between P52 and BCL2 among Iraqi Women with Breast Carcinoma

Al-Sudani¹,

AlKhafaji²,

Mohammed³

2023

Baghdad Sci.J

View full text Add to dashboard Cite

show abstract

“…During quiescence, LEF1 appeared in the outermost layer of the bulge region, and its expression was also markedly enhanced in the inner root sheath below the bulge region, similar to the localization of stem cell markers. BCL2 is an apoptosis-inhibiting gene and is considered an influential factor in tumor cell production and proliferation, and it may play a role in the HF growth cycle and morphogenesis [57][58][59][60]. Its expression in the follicular epithelium is dependent on the cycle.…”

Section: Discussionmentioning

confidence: 99%

Regulation of Hair Follicle Growth and Development by Different Alternative Spliceosomes of FGF5 in Rabbits

Sun,

Zhao,

et al. 2024

Genes

View full text Add to dashboard Cite

This study investigated the regulatory effect of alternative spliceosomes of the fibroblast growth factor 5 (FGF5) gene on hair follicle (HF) growth and development in rabbits. The FGF5 alternative spliceosomes (called FGF5-X1, FGF5-X2, FGF5-X3) were cloned. The overexpression vector and siRNA of spliceosomes were transfected into dermal papilla cells (DPCs) to analyze the regulatory effect on DPCs. The results revealed that FGF5-X2 and FGF5-X3 overexpression significantly decreased LEF1 mRNA expression (p < 0.01). FGF5-X1 overexpression significantly reduced CCND1 expression (p < 0.01). FGF5-X1 and FGF5-X2 possibly downregulated the expression level of FGF2 mRNA (p < 0.05), and FGF5-X3 significantly downregulated the expression level of FGF2 mRNA (p < 0.01). The FGF5 alternative spliceosomes significantly downregulated the BCL2 mRNA expression level in both cases (p < 0.01). FGF5-X1 and FGF5-X2 significantly increased TGFβ mRNA expression (p < 0.01). All three FGF5 alternative spliceosomes inhibited DPC proliferation. In conclusion, the expression profile of HF growth and development-related genes can be regulated by FGF5 alternative spliceosomes, inhibiting the proliferation of DPCs and has an influence on the regulation of HF growth in rabbits. This study provides insights to further investigate the mechanism of HF development in rabbits via FGF5 regulation.

show abstract

“…Экспрессия мутантного p53 может быть связана с потерей экспрессии Bcl-2 и повышением клеточной пролиферации. В исследованиях показана негативная прогностическая роль гиперэкспрессии белка р53, который ассоциирован с низкой степенью дифференцировки, отсутствием экспрессии рецепторов эстрогена, отсутствием ответа на химиотерапию, снижением показателей выживаемости [27]. В исследованиях обнаружено, что большинство опухолей при тройном негативном фенотипе РМЖ с мутацией BRCA1 также демонстрируют и наличие мутации TP53 [28].…”

Section: опухоли женской репродуктивной системы Tumors Of Female Repr...unclassified

Tumor immune microenvironment and apoptotic markers in breast cancer patients carrying <I>BRCA1</I> gene mutations

Stukan

Goryainova

Andreev

et al. 2022

Opuholi ženskoj reproduktivnoj sistemy

View full text Add to dashboard Cite

Background. It is suggested that defects in BRCA1 / 2 genes contribute to a high mutational load and high immunogenicity, which modulates immune microenvironment. At the same time, it was shown that BRCA1 / 2-associated breast cancer tumors do not belong to the category of immunoactive ones. These tumors have low expression of immune response genes and exhibit an immunosuppressive type of microenvironment. This indicates the need of antitumor immune response modulation and maintaining of the optimal balance of tumor CD4/CD8 T-lymphocytes ratio. In addition, there is evidence of the additional evaluation of TP53 mutation in these tumors and disruption of the cell death process, which can also be a factor of resistance to therapy, including PARP inhibitors, and serve as a therapeutic target.Materials and methods. The prospective study included 20 patients with BRCA1-associated breast cancer. BRCA1 / 2 mutations (BRCA1 185delAG, 4153delA, 5382insC, 3819delGTAAA, 3875delGTCT, 300T>G, 2080delA, BRCA2 6174delT) were detected in by real-time polymerase chain reaction. Immunohistochemical study was performed on paraffin embedded tissue blocks by an automated method on a ThermoScentific immunohistotainer using monoclonal antibodies. The expression of markers of tumor-infiltrating CD4+ and CD8+ T-lymphocytes, markers of macrophages (CD68, CD163), apoptosis (Bcl-2, p53), cell adhesion markers (E-cadherin, β-catenin) in breast cancer in carriers of BRCA1 mutations was assessed.Results. High CD4/CD8 ratio, which characterizes immunosuppressive microenvironment, occurred in 75 % of cases. BRCA1 5382insC mutation is associated with high level of CD4+ TILs (p˂0.05), G2 is associated with a low CD4/CD8 ratio (p = 0.039) and a high level of CD163 (p = 0.02, AUC = 0.739); T1 correlates with high levels of CD8+ TILs (p = 0.038) and high levels of CD163 (p = 0.033). High Ki-67 is associated with a lack of Bcl-2 expression (p = 0.04) and a low level of E-cadherin (p = 0.02). Negative expression of Bcl-2 occurred in 75 % of cases. High level of p53 expression has been described as the main type of expression in these tumors, suggesting a combination of TB53 and BRCA1 mutations and a violation of cell death mechanism of in these tumors.Conclusion. Breast cancer tumors of patients with hereditary mutations in BRCA1 gene demonstrate immunosuppressive type of microenvironment and a violation of the cell death mechanism. The main directions of future therapy of these tumors may include tumor immune microenvironment modification and activation of cell death mechanisms.

show abstract

Combined p53 and Bcl2 Immunophenotypes in Prognosis of Vietnamese Invasive Breast Carcinoma: A Single Institutional Retrospective Analysis

Cited by 7 publications

References 34 publications

Correlation Expression between P52 and BCL2 among Iraqi Women with Breast Carcinoma

Correlation Expression between P52 and BCL2 among Iraqi Women with Breast Carcinoma

Regulation of Hair Follicle Growth and Development by Different Alternative Spliceosomes of FGF5 in Rabbits

Tumor immune microenvironment and apoptotic markers in breast cancer patients carrying <I>BRCA1</I> gene mutations

Contact Info

Product

Resources

About